MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ALGS had $23,285K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$23,285K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
-31,537 27,225
Accretion of discount on investments
710 1,034
Non cash lease expense
478 905
Change in fair value of 2023 common warrants
4,205 -63,176
Depreciation expense
220 453
Stock-based compensation including espp
1,467 2,119
Other assets
-587 -190
Accounts payable
752 1,328
Accrued liabilities
1,400 -3,352
Operating lease liabilities
-796 -1,499
Deferred revenue
-411 428
Net cash and cash equivalents used in operating activities
-24,345 -36,413
Maturities of short-term investments
70,000 20,000
Purchase of short-term investments
22,124 103,336
Purchases of property and equipment
-193 -152
Net cash and cash equivalents used in investing activities
47,683 -83,488
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs
-43 101,386
Payments on finance lease
10 1
Proceeds from the espp purchase
0 180
Net cash and cash equivalents provided by financing activities
-53 101,565
Net increase (decrease) in cash, cash equivalents, and restricted cash
23,285 -18,336
Cash and cash equivalents at beginning of period
37,107 -
Cash and cash equivalents at end of period
42,056 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc. (ALGS)